Fundraising Fox
Cambridge · Seed–Series A · 9 people tracked
Also known as CURIE BIO OPERATIONS, LLC
Find your way into Curie.Bio
Sign up to see every warm intro you have to Curie.Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Curie.Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Curie.Bio backs founders building new therapeutics across any modality, therapeutic area, or geography, from concept stage through clinical proof-of-concept. It invests through two vehicles: a Seed Fund writing $5-15M checks to reach preclinical milestones such as a development candidate, and a Breakout Fund providing roughly $35-70M to advance medicines through clinical trials. Beyond funding, the firm deploys a team of 100+ experienced drug makers, drug hunters, and operators who embed with portfolio companies to shape R&D strategy, design experiments with CROs, recruit talent, and raise follow-on capital, aiming for a capital-efficient path to the clinic.
Source: firm website, verified Oct 1, 2026.
Team · 9 people
from curated & public directories
Founder mafia
The Curie.Bio mafia →6 people who came through Curie.Bio went on to found or lead other companies.
What they invest in
from 7 of 8 portfolio companiesAI & Machine Learning ×5SaaS ×3Biotech ×2Enterprise Software ×2Fintech ×2Creator Economy ×1Cybersecurity ×1Data & Infrastructure ×1
HQs:United States×4Singapore×1
Investments · 8 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 22022 · 12021 · 12020 · 16 dated
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.
AI & Machine LearningBiotechDeep TechCambridge, US
Donald A. Bergstrom(Executive Officer)inSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)
Board seatAlexis Borisy· per SEC Form D · $30M raise · filed Jan 2024
Co-investorsCommonweal VenturesEcoR1 CapitalForesite CapitalNat TurnerNextech InvestSoftBank Vision Fund+2 more
Forward Therapeutics develops oral small-molecule medicines targeting inflammation-driven diseases, using a structure-based, data-driven discovery engine to design drugs against validated pathways.
AI & Machine LearningBiotech
Co-investorsOrbiMed
Flossy builds AI agents that handle conversations, scheduling, and performance coaching for dental practice front offices.
AI & Machine LearningHealthtechSaaS
Miles Beckett(Founder)inSteve Seigel(Founder)in
Co-investorsAct One VenturesB Capital GroupB4 CapitalClocktower VenturesEverywhere VenturesGreen Meadow Ventures+14 more
.jpeg){kind=logo}
Iru is an AI-powered unified platform for IT and security teams that consolidates endpoint management, identity, threat detection, vulnerability management, and compliance automation.
AI & Machine LearningCybersecurityEnterprise Software
Adam Pettit(Founder)Mark Daughters(Founder)Wesley Pettit(Founder)
Co-investors515 VenturesB Capital GroupB4 CapitalFelicis VenturesFirst Round CapitalFrontline Ventures+26 more
Peakflo is a SaaS platform that automates financial operations workflows for B2B businesses, including invoice-to-cash, procure-to-pay, travel and expense reimbursement, and general operations.
AI & Machine LearningEnterprise SoftwareFintechSaaSSingapore, SG
Saurabh Chauhan(Founder)inDmitry Vedenyapin(Founder)inAnirudh Bhaskaran(Entrepreneur In Residence)Hari Nuti(Founder)Karim Sulisto(Commercial Lead)Cindy Wijaya(CSM)
Co-investorsEntrepreneur FirstSoma CapitalY Combinator468 CapitalAmino CapitalCE Innovation Capital+5 more
-2.png)
Co-investorsF-Prime CapitalAbingworth
Tubular provides a video analytics and audience insights platform that helps content strategists identify trending topics, benchmark performance across social platforms, and find gaps in content demand.
Creator EconomyData & InfrastructureMarketing TechMedia & EntertainmentMountain View, US
Rob Gabel(Founder)inAllison Stern(Founder)
BoardMatt Coffin(Director)Rick Heitzmann(Director)inAllen DeBevoise(Director)Warren Lee(Director)in
Co-investorsBling CapitalCanaan PartnersLerer HippeauMarkerAME Cloud VenturesAmplify.LA+16 more
Zeal is an embedded payroll and workforce payments platform for staffing companies, labor marketplaces, and workforce management tools.
FintechHR TechSaaSSan Francisco, US
Pranab Krishnan(Founder)inKirti Shenoy(Founder)inJonathan MairenaHenry Guillen(Founding Engineer)Alex Dees(Partner Growth Manager)Grace Turner(Lead Recruiter)
Co-investorsCommerce VenturesSpark CapitalBoxGroupCohen CircleLorimer VenturesY Combinator+15 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
1 IPOs · 1 acquisitions · showing 1RelayNASDAQ: RLAY
Frequently asked questions
- How many investments has Curie.Bio made?
- Curie.Bio has 8 tracked investments, 2 of which have exited, including 1 dated in the last 24 months.
- What stage does Curie.Bio invest at?
- Curie.Bio invests at the Seed, Series A stages.
- What is Curie.Bio's typical check size?
- Curie.Bio typically writes checks of $5M – $15M.
- What sectors does Curie.Bio focus on?
- Curie.Bio focuses on Biotech, Healthtech.
- Where is Curie.Bio located?
- Curie.Bio is headquartered in Cambridge, US.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.